Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
TAKEDA ANNOUNCES LAUNCH OF EXCHANGE OFFER FOR ANY AND ALL OF ITS $1.250 BILLION 4.000% SENIOR NOTES DUE 2021, $1.500 BILLION 4.400% SENIOR NOTES DUE 2023 AND $1.750 BILLION 5.000% SENIOR NOTES DUE 2028
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
SEE ALL NEWS AND RELEASES >
・For legacy Shire information, click here
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2019 Takeda Pharmaceutical Company Limited. All rights reserved.